Is inhaled budesonide indicated for a chronic cough?

Inhaled Budesonide for Chronic Cough

Budesonide is indicated for chronic cough ONLY when the cough is caused by cough variant asthma (CVA) or non-asthmatic eosinophilic bronchitis (NAEB), not for chronic cough in general. 1

When to Use Budesonide

Cough Variant Asthma (CVA)

• Inhaled corticosteroids (ICS) like budesonide should be first-line treatment for chronic cough due to CVA (Grade 1B recommendation) 1
• CVA presents as isolated chronic cough without wheezing or dyspnea, but with airway hyperresponsiveness on bronchial challenge testing (e.g., methacholine)
• These patients typically have eosinophilic airway inflammation

Non-Asthmatic Eosinophilic Bronchitis (NAEB)

• ICS are first-choice treatment for NAEB (Grade 2B recommendation) 1
• NAEB presents with chronic cough and sputum eosinophilia (>3% eosinophils) but WITHOUT airway hyperresponsiveness or variable airflow obstruction
• Research confirms budesonide 400 mcg twice daily significantly reduces sputum eosinophilia (from 12.8% to 2.9%), improves cough severity, and decreases cough reflex sensitivity 2

When NOT to Use Budesonide

Budesonide is NOT effective and should NOT be used for:

• Post-viral cough (post-URTI): A randomized controlled trial showed budesonide 400 mcg twice daily was completely ineffective compared to placebo for persistent cough following upper respiratory tract infections 3
• Chronic cough without eosinophilia: Research demonstrates budesonide has no effect on chronic cough in patients without sputum eosinophilia 4
• Upper airway cough syndrome (UACS): Only modest efficacy with short-course treatment 5
• Unexplained chronic cough (UCC): Limited benefit unless eosinophilic inflammation is present 5

Diagnostic Algorithm Before Prescribing

Before prescribing budesonide, you must establish the underlying cause:

1. Measure airway inflammation markers (Grade 2B) 1:

   • Induced sputum eosinophil count (>3% suggests eosinophilic disease)
   • Fractional exhaled nitric oxide (FeNO)
   • Blood eosinophil count

2. Perform bronchial challenge testing (methacholine):

   • Positive = CVA (treat with ICS)
   • Negative + sputum eosinophilia = NAEB (treat with ICS)
   • Negative + no eosinophilia = Consider other causes (ICS unlikely to help)

3. Rule out other causes: GERD, ACE inhibitor use, post-nasal drip, bronchiectasis

Dosing and Treatment Strategy

Initial treatment:

• Budesonide 400 mcg twice daily (or equivalent ICS dose) 2, 6
• Continue for at least 4 weeks to assess response 2
• Maximum benefit may take 4-6 weeks 7

If incomplete response:

• Step up ICS dose (e.g., to 800 mcg/day budesonide) 1
• Add leukotriene receptor antagonist (montelukast) 1, 6
• For CVA, consider adding beta-agonist 1
• Reconsider alternative diagnoses before escalating

Predictors of Poor Response

Budesonide is less likely to work if: 5

• Cough duration ≥52 weeks (though extended treatment beyond 2 weeks may still help)
• Cough NOT triggered by cold air exposure
• Absence of sputum eosinophilia 4

Critical Pitfalls to Avoid

1. Do not prescribe budesonide empirically for all chronic cough—it only works for eosinophilic airway diseases
2. Do not use for acute cough or acute asthma exacerbations 7—budesonide is maintenance therapy only
3. Do not stop after 1-2 weeks if there's partial improvement—full benefit requires 4-6 weeks 7
4. FDA approval is only for children 12 months to 8 years for asthma maintenance 7—adult use for chronic cough is off-label but guideline-supported

Safety Considerations

• Generally well-tolerated with short-term use
• Most common adverse effect: mild hoarse voice (5-6% of patients) 5
• Monitor for systemic corticosteroid effects with prolonged use 7
• Not appropriate for patients with untreated infections (fungal, bacterial, TB) 7